Bisphosphonates are pyrophosphate analogs with a high affinity for calcium crystals. Due to the affinity of bisphosphonates for calcium, they bind rapidly to calcium-containing hydroxyapatite crystals, especially in the resorption zone. In this way, they prevent bone resorption. In this study, we aimed to investigate the effect of bisphosphonate use on treatment response and overall survival in patients with MM.

All patients with MM who followed by the Hematology department of Fırat University Hospital in the last 10 years were included in this retrospective observational study. Age, gender, end-organ involvement, ISS staging, LDH level, IG subtype in diagnosis, bisphosphonate use (duration and dose), treatments, response status and survival was investigated.

Ninety-one patients, of whom 53 were male and 38 females, were included in this study. At the time of diagnosis,14 patients with high calcium, 77 patients had normal calcium. There was no significant difference in survival between bisphosphonate intake status and IG subtypes (p>0,05). There was no significant difference in progression-free survival between the ISS category, bisphosphonate intake status, creatinine category, and IG subtypes (p>0,05).

In this study, OS, and PFS in MM patients were not affected by bisphosphonate use. however, LDH level influenced both OS and PFS, the increase in LDH level negatively affected the survival.